Epidermal growth factor receptor (EGFR) promotes uptake of bovine parainfluenza virus type 3 into MDBK cells

Wei Pan1, Yaodong Xia1, Hongmei Wang1

  • 1Ruminant Diseases Research Center, College of Life Sciences, Shandong Normal University, Jinan 250014, China; Key Laboratory of Animal Resistant Biology of Shandong, College of Life Sciences, Shandong Normal University, Jinan 250014, China.

Insights

Bovine parainfluenza virus 3 (BPIV3) uses the Epidermal Growth Factor Receptor (EGFR) to enter cattle cells. EGFR activation is crucial for viral entry and cytoskeleton changes, impacting BPIV3 infection.

Area of Science:

  • Virology
  • Cell Biology
  • Molecular Biology

Background:

  • Bovine parainfluenza virus 3 (BPIV3) causes significant respiratory illness in cattle.
  • Viral entry mechanisms are key to understanding BPIV3 transmission and disease.
  • Previous work identified macropinocytosis and clathrin-dependent endocytosis in BPIV3 entry.

Purpose of the Study:

  • To investigate the role of Epidermal Growth Factor Receptor (EGFR) in BPIV3 cell entry.
  • To elucidate the signaling pathways downstream of EGFR involved in BPIV3 infection.

Main Methods:

  • Utilized specific EGFR inhibitors and siRNAs to block BPIV3 entry into MDBK cells.
  • Assessed EGFR activation and F-actin cytoskeleton rearrangement during BPIV3 infection.
  • Analyzed the activation of downstream signaling pathways (PI3K-Akt, ERK1/2) and macropinocytosis regulators (Rac1, Pak1).

Main Results:

  • EGFR inhibition significantly reduced BPIV3 entry into MDBK cells.
  • BPIV3 infection activated EGFR, which was essential for F-actin cytoskeleton remodeling.
  • EGFR-dependent activation of PI3K-Akt and ERK1/2 pathways, as well as Rac1 and Pak1, was observed.
  • Inhibiting these downstream pathways also reduced viral entry efficacy.

Conclusions:

  • EGFR acts as a host-entry cofactor for BPIV3 in MDBK cells.
  • EGFR signaling is critical for BPIV3-mediated cytoskeletal changes and viral internalization.
  • Targeting EGFR and its downstream pathways presents a potential strategy for controlling BPIV3 infections.